Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.46 |
| ▸ | NT5E | P21589 | 4/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067078 | 0.90 | GPR17 (0.51) | ADORA3ADORA1NT5EADORA2BP2RY1 | |
| SCHEMBL18067076 | 0.90 | P2RY1 (0.51) | ADORA3ADORA1NT5EADORA2BP2RY1 | |
| SCHEMBL24790445 | 0.90 | ADORA3 (0.41) | ADORA3ADORA1NT5EADORA2BP2RY1 | |
| SCHEMBL30091038 | 0.90 | ADORA3 (0.41) | ADORA3ADORA1NT5EADORA2BP2RY1 | |
| At-9010 SCHEMBL18067079 | 0.90 | GPR17 (0.52) | ADORA3ADORA1NT5EADORA2BP2RY1 | |
| At-9010 SCHEMBL25844490 | 0.90 | GPR17 (0.52) | ADORA3ADORA1NT5EADORA2BP2RY1 | |
| SCHEMBL18061561 | 0.87 | ADORA3 (0.44) | ADORA3ADORA1NT5EADORA2BP2RY1 | |
| SCHEMBL19644763 | 0.87 | ADORA3 (0.44) | ADORA3ADORA1NT5EADORA2BP2RY1 | |
| SCHEMBL22837340 | 0.85 | ADORA3 (0.49) | ADORA3ADORA1NT5EADORA2BP2RY1 | |
| SCHEMBL19828113 | 0.83 | ADORA1 (0.52) | ADORA3ADORA1NT5EADORA2BP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | ADORA3 291/4885ADORA1 244/4885NT5E 96/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | ADORA3 291/4885ADORA1 244/4885NT5E 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.